Core Laboratories (NYSE:CLB) Upgraded at Citigroup

Core Laboratories (NYSE:CLB - Get Free Report) was upgraded by stock analysts at Citigroup from a "sell" rating to a "neutral" rating in a report released on Wednesday,Briefing.com Automated Import reports. The brokerage currently has a $16.00 price objective on the oil and gas company's stock, up from their prior price objective of $15.00. Citigroup's price objective indicates a potential upside of 9.18% from the stock's current price.

Core Laboratories Price Performance

Shares of Core Laboratories stock opened at $14.66 on Wednesday. The company has a current ratio of 2.32, a quick ratio of 1.71 and a debt-to-equity ratio of 0.49. The stock has a market capitalization of $686.25 million, a price-to-earnings ratio of 22.20, a P/E/G ratio of 0.99 and a beta of 2.38. Core Laboratories has a 1-year low of $12.95 and a 1-year high of $25.13. The firm's 50-day moving average price is $17.28 and its two-hundred day moving average price is $18.39.

Core Laboratories (NYSE:CLB - Get Free Report) last released its quarterly earnings results on Wednesday, January 29th. The oil and gas company reported $0.23 EPS for the quarter, meeting the consensus estimate of $0.23. Core Laboratories had a net margin of 5.99% and a return on equity of 16.24%. On average, equities analysts predict that Core Laboratories will post 0.96 earnings per share for the current fiscal year.

Institutional Trading of Core Laboratories

Hedge funds have recently modified their holdings of the stock. State Street Corp boosted its stake in Core Laboratories by 2.9% in the third quarter. State Street Corp now owns 1,975,016 shares of the oil and gas company's stock valued at $36,597,000 after acquiring an additional 56,187 shares during the last quarter. Geode Capital Management LLC raised its holdings in Core Laboratories by 0.7% in the third quarter. Geode Capital Management LLC now owns 1,053,204 shares of the oil and gas company's stock worth $19,521,000 after purchasing an additional 7,721 shares during the period. Boston Trust Walden Corp raised its holdings in Core Laboratories by 2.7% in the fourth quarter. Boston Trust Walden Corp now owns 617,336 shares of the oil and gas company's stock worth $10,686,000 after purchasing an additional 16,503 shares during the period. Barclays PLC raised its holdings in Core Laboratories by 288.2% in the third quarter. Barclays PLC now owns 83,570 shares of the oil and gas company's stock worth $1,549,000 after purchasing an additional 62,042 shares during the period. Finally, Principal Financial Group Inc. raised its holdings in Core Laboratories by 3.1% in the fourth quarter. Principal Financial Group Inc. now owns 229,096 shares of the oil and gas company's stock worth $3,966,000 after purchasing an additional 6,827 shares during the period. 97.81% of the stock is owned by institutional investors.

Core Laboratories Company Profile

Core Laboratories Inc provides reservoir description and production enhancement services and products to the oil and gas industry in the United States, and internationally. It operates through Reservoir Description and Production Enhancement segments. The Reservoir Description segment includes the characterization of petroleum reservoir rock and reservoir fluid samples to enhance production and improve recovery of crude oil and gas from its clients' reservoirs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Remove Ads